Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12465407rdf:typepubmed:Citationlld:pubmed
pubmed-article:12465407lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:12465407lifeskim:mentionsumls-concept:C0543467lld:lifeskim
pubmed-article:12465407lifeskim:mentionsumls-concept:C0278553lld:lifeskim
pubmed-article:12465407lifeskim:mentionsumls-concept:C0123931lld:lifeskim
pubmed-article:12465407lifeskim:mentionsumls-concept:C1446539lld:lifeskim
pubmed-article:12465407lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:12465407pubmed:issue11lld:pubmed
pubmed-article:12465407pubmed:dateCreated2002-12-5lld:pubmed
pubmed-article:12465407pubmed:abstractTextOne patient with pulmonary metastasis from colon cancer and one with para-aortic lymph node metastasis were treated with a combination of irinotecan and UFT. Irinotecan (100 mg/m2) was given by 24-hour intravenous infusion on day 1, and UFT (600 mg/day) was given orally on days 3 to 7 and days 10 to 14 of a 2-week course, which was then repeated. In the patient with pulmonary metastasis, the lesions in the lung resolved after 7 courses of chemotherapy. Surgery was performed after 10 courses. The patient with para-aortic lymph node metastasis had a partial response after 4 courses of chemotherapy, and underwent surgery after 6 courses. The only adverse effects were grade 2 myelosuppression and hair loss, none of which were severe enough to require treatment. With this chemotherapy regimen, patients are admitted for two days biweekly for 24-hour intravenous infusion of CPT-11. Thus, most of the treatment can be performed on an outpatient basis. The combination of irinotecan and UFT is expected to be useful for metastatic or recurrent colon cancer.lld:pubmed
pubmed-article:12465407pubmed:languagejpnlld:pubmed
pubmed-article:12465407pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12465407pubmed:citationSubsetIMlld:pubmed
pubmed-article:12465407pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12465407pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12465407pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12465407pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12465407pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12465407pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12465407pubmed:statusMEDLINElld:pubmed
pubmed-article:12465407pubmed:monthNovlld:pubmed
pubmed-article:12465407pubmed:issn0385-0684lld:pubmed
pubmed-article:12465407pubmed:authorpubmed-author:YasudaSeieiSlld:pubmed
pubmed-article:12465407pubmed:authorpubmed-author:SadahiroSotar...lld:pubmed
pubmed-article:12465407pubmed:authorpubmed-author:MakuuchiHiroy...lld:pubmed
pubmed-article:12465407pubmed:authorpubmed-author:SuzukiToshiyu...lld:pubmed
pubmed-article:12465407pubmed:authorpubmed-author:MaedaYujiYlld:pubmed
pubmed-article:12465407pubmed:authorpubmed-author:IshikawaKenji...lld:pubmed
pubmed-article:12465407pubmed:authorpubmed-author:SaguchiTakesh...lld:pubmed
pubmed-article:12465407pubmed:authorpubmed-author:MurayamaChiek...lld:pubmed
pubmed-article:12465407pubmed:authorpubmed-author:YamamotoTakaa...lld:pubmed
pubmed-article:12465407pubmed:issnTypePrintlld:pubmed
pubmed-article:12465407pubmed:volume29lld:pubmed
pubmed-article:12465407pubmed:ownerNLMlld:pubmed
pubmed-article:12465407pubmed:authorsCompleteYlld:pubmed
pubmed-article:12465407pubmed:pagination2013-8lld:pubmed
pubmed-article:12465407pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:12465407pubmed:meshHeadingpubmed-meshheading:12465407...lld:pubmed
pubmed-article:12465407pubmed:meshHeadingpubmed-meshheading:12465407...lld:pubmed
pubmed-article:12465407pubmed:meshHeadingpubmed-meshheading:12465407...lld:pubmed
pubmed-article:12465407pubmed:meshHeadingpubmed-meshheading:12465407...lld:pubmed
pubmed-article:12465407pubmed:meshHeadingpubmed-meshheading:12465407...lld:pubmed
pubmed-article:12465407pubmed:meshHeadingpubmed-meshheading:12465407...lld:pubmed
pubmed-article:12465407pubmed:meshHeadingpubmed-meshheading:12465407...lld:pubmed
pubmed-article:12465407pubmed:meshHeadingpubmed-meshheading:12465407...lld:pubmed
pubmed-article:12465407pubmed:meshHeadingpubmed-meshheading:12465407...lld:pubmed
pubmed-article:12465407pubmed:meshHeadingpubmed-meshheading:12465407...lld:pubmed
pubmed-article:12465407pubmed:meshHeadingpubmed-meshheading:12465407...lld:pubmed
pubmed-article:12465407pubmed:meshHeadingpubmed-meshheading:12465407...lld:pubmed
pubmed-article:12465407pubmed:meshHeadingpubmed-meshheading:12465407...lld:pubmed
pubmed-article:12465407pubmed:meshHeadingpubmed-meshheading:12465407...lld:pubmed
pubmed-article:12465407pubmed:meshHeadingpubmed-meshheading:12465407...lld:pubmed
pubmed-article:12465407pubmed:meshHeadingpubmed-meshheading:12465407...lld:pubmed
pubmed-article:12465407pubmed:meshHeadingpubmed-meshheading:12465407...lld:pubmed
pubmed-article:12465407pubmed:meshHeadingpubmed-meshheading:12465407...lld:pubmed
pubmed-article:12465407pubmed:year2002lld:pubmed
pubmed-article:12465407pubmed:articleTitle[Two patients with recurrent colon cancer who underwent surgery following a combination of irinotecan and UFT].lld:pubmed
pubmed-article:12465407pubmed:affiliationDept. of Gastrointestinal Surgery, Tokai University Hospital.lld:pubmed
pubmed-article:12465407pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12465407pubmed:publicationTypeEnglish Abstractlld:pubmed
pubmed-article:12465407pubmed:publicationTypeCase Reportslld:pubmed